Skip to content

Microdosing: all studies

Page 7 of 56: studies 61 to 70 of 555, newest first. Back to the microdosing overview

Research

Daily self-assessment within a regimen of microdosing indicates enhanced psychological functioning on microdosing days relative to non-microdosing days.

Psychopharmacology October 11, 2025 Michelle St Pierre, Elena Argento, Jordyn Cates et al.

Repeated self-administration of small doses of psychedelics, known as microdosing, has been associated with perceived improvements in psychological functioning. However, few studies have examined effects at the daily level. Drawing on data from a naturalistic, prospective, international survey of adults who microdose (N = 1435), we assessed self-reported within-person changes between...

How low can you go? Intraoperative microdosing of indocyanine green for fluorescence cholangiography during laparoscopic cholecystectomy.

Surgical endoscopy October 1, 2025 Ryan C Broderick, Graham J Spurzem, Ana Garcia Cabrera et al.

Fluorescence cholangiography (FC) with indocyanine green (ICG) enables real-time intraoperative visualization of extrahepatic biliary anatomy during laparoscopic cholecystectomy (LC). There is no consensus on the optimal ICG dose or timing of administration for LC. The goal of this study was to implement a simple intraoperative low-dose ("microdose") ICG protocol that facilitates non-inferior...

DOI: 10.1007/s00464-025-12057-w (opens in new tab) Full text (opens in new tab) Fluorescence cholangiography Indocyanine green Laparoscopic cholecystectomy Microdose +1

Microdosing Psychedelics for Cognitive Enhancement: A Naturalistic Exploration of User Experiences

September 24, 2025 Luke Pelham

Psychedelics have recently grown in scientific interest, among this, there have been promising findings regarding its potential to treat a range of health problems (such as depression, anxiety, PTSD). Despite the growing research interest in psychedelics, there is little research investigating the effects of microdoses: tiny doses that produce sub-hallucinogenic effects. Additionally, there is...

DOI: 10.26686/tvwc-80bg (opens in new tab) Full text (opens in new tab) Mood Exploratory research Variety cybernetics Naturalistic observation +2

Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.

International Journal of Molecular Sciences September 14, 2025 Jacopo Sapienza, Marco Spangaro, Stefano Comai et al. 2 citations

Schizophrenia is a highly polygenic disease, and several genetic variants associated with the disease converge on altered synaptic homeostasis. In particular, the gene encoding complement component 4 (C4) showed the strongest association with schizophrenia, and this protein is involved in complement-dependent and microglia-mediated synaptic pruning. As a matter of fact, microglia are overactive...

A randomised placebo-controlled study of the effects of lysergic acid diethylamide microdosing (15 μg) on pain perception in healthy volunteers.

British Journal of Pain September 4, 2025 Mauro Cavarra, Nadia R. P. W. Hutten, Jan Schepers et al.

Background: Preliminary research indicates that psychedelics may hold promise as analgesic agents. This study investigated the potential analgesic effects of lysergic acid diethylamide (LSD) microdosing on pain tolerance and subjective pain perception in healthy participants. Methods: Utilizing a randomised, placebo-controlled design, participants received 15 μg of LSD or placebo over four...

Assessing the Potential Cardiovascular Risk of Microdosing the Psychedelic LSD in Mice

ACS Pharmacology & Translational Science August 22, 2025 Devin P. Effinger, Serena S. Schalk, Jillian L. King et al. 3 citations

High Resolution Image Download MS PowerPoint Slide Microdosing, the prolonged ingestion of psychedelics at subhallucinogenic doses, has gained popularity for its perceived cognitive and emotional benefits. Psychedelics have high affinity for 5-HT 2B receptors, a receptor known to cause human heart disease with strong chronic activation. We investigated the effects of microdosed psychedelics on...

504. BEYOND THE HYPE: EXAMINING THE THERAPEUTIC POTENTIAL OF PSYCHEDELIC MICRODOSING THROUGH THE LENS OF EXPERIMENTAL CONTROL AND EVIDENCE

The International Journal of Neuropsychopharmacology August 18, 2025 Orla Mallon

Abstract Background The practice of psychedelic microdosing has grown outside of the medical realm from a community of self-medicating users who endorse improvements in cognitive functioning and mental health. The breadth and strength of this advocacy has led many to replace traditional psychotropic medication and well-being support with an under researched practice. This represents a divide...

Between enhancement and risk: A critical review of psychedelic microdosing

Current Opinion in Psychology August 6, 2025 Iva Totomanova, Eline Haijen, Petra P M Hurks et al. 5 citations

Microdosing psychedelics, the regular use of low doses of LSD or psilocybin, have attracted growing public and scientific interest. This review synthesizes findings from 57 human studies on psychological and physiological outcomes in clinical and non-clinical populations. Reported benefits include improved mood, enhanced cognition, social functioning, and mental health, although findings are...

155. EXPLORING LSD MICRODOSING IN AN OPEN-LABEL PILOT FOR MAJOR DEPRESSIVE DISORDER: THE INTERPLAY OF BEHAVIORAL ACTIVATION, MOOD IMPROVEMENT, AND CONNECTEDNESS

The International Journal of Neuropsychopharmacology August 1, 2025 C Donegan, D Daldagen-Bueno, Robin J Murphy et al.

Abstract Background Depressive disorders affect about 280 million people worldwide, with many struggling to find effective relief. Conventional antidepressants are widely prescribed but often lack efficacy and have side effects, leaving many patients dissatisfied or untreated. Concurrently, psychedelic therapies have gained momentum in both research and ‘in the wild’, with emerging evidence...

Exploring Microdosing Psychedelics as a Self-Managed Treatment for Premenstrual Dysphoric Disorder: A Qualitative Study

July 25, 2025 Rachael Sumner, Yuxin Ni, Suresh Muthukumaraswamy preprint

Background: Premenstrual dysphoric disorder (PMDD) is a severe mood disorder characterised by depression, irritability, mood lability, anxiety and physical symptoms that occur exclusively in the last week/s of the menstrual cycle. With a growing global interest in microdosing of psychedelic drugs, an increase in self-medication has occurred, including by those with PMDD. Aim: Qualitative...

DOI: 10.31219/osf.io/hq8ps_v1 (opens in new tab) Premenstrual dysphoric disorder Psychotherapist Qualitative research Clinical psychology